Synta's (SNTA) Ganetespib Could See Extra Exclusivity Following FDA Meeting - Roth
Tweet Send to a Friend
Roth Capital maintains Synta Pharma (Nasdaq: SNTA) with a Buy rating and price target of $27 following news that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
